Cargando…
Clozapine is the approved option in treatment-resistant schizophrenia and requires careful management
Clozapine is the only agent approved for treatment-resistant schizophrenia, but is underprescribed. Its adverse drug event (ADE) profile and patient monitoring requirements can discourage its use, but the benefits of clozapine generally outweigh its risks, as most ADEs are manageable. Careful patien...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936483/ https://www.ncbi.nlm.nih.gov/pubmed/36811119 http://dx.doi.org/10.1007/s40267-023-00982-6 |